Pharmacological Targeting of the Hepcidin/Ferroportin Axis
Open Access
- 21 June 2016
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 7, 160
- https://doi.org/10.3389/fphar.2016.00160
Abstract
The iron regulatory hormone hepcidin limits iron fluxes to the bloodstream by promoting degradation of the iron exporter ferroportin in target cells. Hepcidin insufficiency causes hyperabsorption of dietary iron, hyperferremia and tissue iron overload, which are hallmarks of hereditary hemochromatosis. Similar responses are also observed in iron-loading anemias due to ineffective erythropoiesis (such as thalassemias, dyserythropoietic anemias and myelodysplastic syndromes) and in chronic liver diseases. On the other hand, excessive hepcidin expression inhibits dietary iron absorption and leads to hypoferremia and iron retention within tissue macrophages. This reduces iron availability for erythroblasts and contributes to the development of anemias with iron-restricted erythropoiesis (such as anemia of chronic disease and iron-refractory iron-deficiency anemia). Pharmacological targeting of the hepcidin/ferroportin axis may offer considerable therapeutic benefits by correcting iron traffic. This review summarizes the principles underlying the development of hepcidin-based therapies for the treatment of iron-related disorders, and discusses the emerging strategies for manipulating hepcidin pathways.Funding Information
- Canadian Institutes of Health Research (MOP-86514)
This publication has 98 references indexed in Scilit:
- Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in miceJCI Insight, 2013
- Pharmacological Suppression of Hepcidin Increases Macrophage Cholesterol Efflux and Reduces Foam Cell Formation and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overloadJCI Insight, 2011
- β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolismBlood, 2011
- Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic miceJCI Insight, 2010
- BMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout MiceGastroenterology, 2010
- Ferroportin disease: A systematic meta-analysis of clinical and molecular findingsJournal of Hepatology, 2010
- Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelatorBlood, 2009
- Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolismNature Chemical Biology, 2007
- Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosisNature Genetics, 2003